Beyond Air Soars 5.42% on Premier Contract

On July 22, 2025, Beyond Air's stock surged by 5.42% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Beyond Air has secured a premier contract with Premier, Inc., granting the company access to two-thirds of the U.S. hospital market. This agreement is expected to streamline the adoption process for Beyond Air's innovative cylinder-free nitric oxide system, which is designed to improve patient outcomes and operational efficiency in hospitals.

Beyond Air's LungFit, a cylinder-free, phasic flow generator and delivery system, has been designated as a medical device by the U.S. Food and Drug Administration (FDA). This designation underscores the company's commitment to developing cutting-edge medical technologies that address critical healthcare needs.